Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2010 1
2013 1
2014 1
2015 1
2016 2
2017 3
2018 1
2019 4
2020 4
2021 5
2022 8
2023 18
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

43 results

Results by year

Filters applied: . Clear all
Page 1
Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial.
Otsubo K, Kishimoto J, Ando M, Kenmotsu H, Minegishi Y, Horinouchi H, Kato T, Ichihara E, Kondo M, Atagi S, Tamiya M, Ikeda S, Harada T, Takemoto S, Hayashi H, Nakatomi K, Kimura Y, Kondoh Y, Kusumoto M, Ichikado K, Yamamoto N, Nakagawa K, Nakanishi Y, Okamoto I. Otsubo K, et al. Among authors: takemoto s. Eur Respir J. 2022 Dec 15;60(6):2200380. doi: 10.1183/13993003.00380-2022. Print 2022 Dec. Eur Respir J. 2022. PMID: 35361630 Clinical Trial.
A case of drug-induced organizing pneumonia caused by amikacin liposome inhalation suspension.
Takao D, Takeda K, Takazono T, Ozasa M, Ito Y, Ashizawa N, Hirayama T, Iwanaga N, Takemoto S, Ide S, Tashiro M, Hosogaya N, Kido T, Sakamoto N, Obase Y, Okano S, Izumikawa K, Yanagihara K, Mukae H. Takao D, et al. Among authors: takemoto s. J Infect Chemother. 2023 Aug;29(8):806-808. doi: 10.1016/j.jiac.2023.04.013. Epub 2023 Apr 23. J Infect Chemother. 2023. PMID: 37098378
Liquid biopsy detects genomic drivers in NSCLC without EGFR mutations by single-plex testing: WJOG13620L.
Uemura T, Kenmotsu H, Hazama D, Teraoka S, Kobe H, Azuma K, Yamaguchi T, Masuda T, Yokoyama T, Otsubo K, Haratani K, Hayakawa D, Oki M, Takemoto S, Ozaki T, Akashi Y, Hata A, Hashimoto H, Yamamoto N, Nakagawa K. Uemura T, et al. Among authors: takemoto s. Cancer Med. 2023 Dec;12(23):21097-21110. doi: 10.1002/cam4.6668. Epub 2023 Nov 10. Cancer Med. 2023. PMID: 37948122 Free PMC article.
Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers.
Kurose K, Sakaeda K, Fukuda M, Sakai Y, Yamaguchi H, Takemoto S, Shimizu K, Masuda T, Nakatomi K, Kawase S, Tanaka R, Suetsugu T, Mizuno K, Hasegawa T, Atarashi Y, Irino Y, Sato T, Inoue H, Hattori N, Kanda E, Nakata M, Mukae H, Oga T, Oka M. Kurose K, et al. Among authors: takemoto s. Adv Clin Chem. 2023;112:155-204. doi: 10.1016/bs.acc.2022.09.004. Epub 2022 Nov 17. Adv Clin Chem. 2023. PMID: 36642483 Review.
Drug-induced interstitial lung disease caused by olaparib: three case reports and review of the Japanese Adverse Drug Event Report database and literature.
Ishimoto H, Sakamoto N, Kido T, Ozasa M, Tsutsui S, Mori M, Setoguchi D, Takemoto S, Obase Y, Ishimatsu Y, Tomonaga C, Matsumoto K, Morisaki S, Miura K, Mukae H. Ishimoto H, et al. Among authors: takemoto s. BMC Pulm Med. 2023 Aug 8;23(1):289. doi: 10.1186/s12890-023-02569-3. BMC Pulm Med. 2023. PMID: 37553592 Free PMC article. Review.
Ramucirumab Plus Docetaxel for Patients with Non-small cell Lung Cancer with Brain Metastases: A Multicenter, Open-Label Single-Arm Phase II Trial.
Tanimura K, Uchino J, Kimura H, Hiranuma O, Chihara Y, Tanzawa S, Takumi C, Kita T, Inoue K, Minato K, Takemoto S, Nakao A, Yoshimura K, Takayama K. Tanimura K, et al. Among authors: takemoto s. Oncologist. 2023 Jun 2;28(6):551-e454. doi: 10.1093/oncolo/oyad013. Oncologist. 2023. PMID: 37053467 Free PMC article. Clinical Trial.
Genetic profile of thymic epithelial tumors in the Japanese population: an exploratory study examining potential therapeutic targets.
Shimada M, Taniguchi H, Yamaguchi H, Gyotoku H, Sasaki D, Kaku N, Senju C, Senju H, Imamura E, Takemoto S, Yamamoto K, Sakamoto N, Obase Y, Tsuchiya T, Fukuda M, Soda H, Ashizawa K, Fukuoka J, Nagayasu T, Yanagihara K, Mukae H. Shimada M, et al. Among authors: takemoto s. Transl Lung Cancer Res. 2023 Apr 28;12(4):707-718. doi: 10.21037/tlcr-22-794. Epub 2023 Mar 23. Transl Lung Cancer Res. 2023. PMID: 37197618 Free PMC article.
High levels of AXL expression in untreated EGFR-mutated non-small cell lung cancer negatively impacts the use of osimertinib.
Yoshimura A, Yamada T, Serizawa M, Uehara H, Tanimura K, Okuma Y, Fukuda A, Watanabe S, Nishioka N, Takeda T, Chihara Y, Takemoto S, Harada T, Hiranuma O, Shirai Y, Shukuya T, Nishiyama A, Goto Y, Shiotsu S, Kunimasa K, Morimoto K, Katayama Y, Suda K, Mitsudomi T, Yano S, Kenmotsu H, Takahashi T, Takayama K. Yoshimura A, et al. Among authors: takemoto s. Cancer Sci. 2023 Feb;114(2):606-618. doi: 10.1111/cas.15608. Epub 2022 Nov 11. Cancer Sci. 2023. PMID: 36169649 Free PMC article.
Phase II study of IRInotecan treatment after COmbined chemo-immunotherapy for extensive-stage small cell lung cancer: Protocol of IRICO study.
Tomono H, Taniguchi H, Fukuda M, Ikeda T, Nagashima S, Akagi K, Ono S, Umeyama Y, Shimada M, Gyotoku H, Takemoto S, Hisamatsu Y, Morinaga R, Tagawa R, Ogata R, Dotsu Y, Senju H, Soda H, Nakatomi K, Hayashi F, Sugasaki N, Kinoshita A, Mukae H. Tomono H, et al. Among authors: takemoto s. Thorac Cancer. 2023 Oct;14(28):2890-2894. doi: 10.1111/1759-7714.15097. Epub 2023 Sep 7. Thorac Cancer. 2023. PMID: 37675546 Free PMC article.
[Trends in Outpatient Chemotherapy for Thoracic Oncology].
Fukuda M, Yamaguchi H, Takemoto S, Senju H, Gyotoku H, Dotsu Y, Umeyama Y, Tsuchiya A, Ikeda T, Nose S, Honda T, Kobayashi K, Ishii K, Mukae H, Ashizawa K. Fukuda M, et al. Among authors: takemoto s. Gan To Kagaku Ryoho. 2020 Oct;47(10):1461-1464. Gan To Kagaku Ryoho. 2020. PMID: 33130741 Japanese.
43 results